Each building of the standardization system further enhances protection for innovation.

Following the ISO27001 information security management system certification, TOT BIOPHARM (Stock code: 1875.HK) has recently received good news that the company has successfully passed the GB/T29490-2013 enterprise intellectual property management system certification, which means that TOT BIOPHARM has established a set of well-conceived and standardized intellectual property management system in line with national standards, and it is also another validation of TOT BIOPHARM’s commitment of respecting intellectual property rights, safeguarding the legal rights of clients, and protecting innovation for customers and partners.

The Enterprise Intellectual Property Management Standard (GB/T29490-2013) is a national standard formulated by the China National Intellectual Property Administration. “Implementation of The Standard”, that is, implementation of the The Enterprise Intellectual Property Management Standard, which is the most effective way for enterprises to integrate IP. This certification on “Implementation of The Standard” strengthens the comprehensive management by TOT BIOPHARM over IP and further enhance the company’s capability in IP management.

IP protection is a key concern for every pharmaceutical enterprise, and it is especially important for CDMO companies to manage IP effectively to protect innovative results of their clients. This certification will put standardized IP management into practices through all aspects including the R&D and manufacture, thus further enhancing the security and standardization of TOT BIOPHARM’s CDMO services, and ensuring customers’ peace of mind by protecting their IP in an effective way.

TOT BIOPHARM is committed to being a better biopharmaceutical partner leading the industry and trusted by customers. With extensive practical experience, as well as sophisticated technology platform and quality system, we provide customized one-stop CDMO solutions for biopharmaceuticals from R&D to commercial manufacture based on the needs of different partners. As well, TOT BIOPHARM will continue to strengthen and improve the management of intellectual property rights and maintain the effective and continuous operation of the system in order to live up to the trust of our clients and protect the development of CDMO business.